

VETMIC® Dogs

Detailed Observational Study Summary

The 4-week observational study was conducted at the veterinary clinic of **Dr. Aneta Bochenska** in Wrocław (Breslau), Poland in 2025.

The program focused on documenting the use of VETMIC® Dogs in everyday clinical settings.

1. Study Objective

The aim of the study was to evaluate the effectiveness of the **VETMIC® Dogs** preparation in dogs suffering from chronic musculoskeletal disorders, including joint degeneration (*osteoarthritis, OA*), spinal diseases, and autoimmune inflammatory joint conditions.

2. Study Population Characteristics

The preparation was administered to **57 canine patients**, and feedback was received from the owners of **51 dogs** (*response rate: 89.5%*). The preparation was used over a period of **4 consecutive weeks** in all included cases.

Study Group

- **38 senior dogs** (aged over 10 years) with advanced degenerative joint disease (*74.5% of the total with feedback*)
 - All were diagnosed with **severe or very severe osteoarthritis** of the hip and/or elbow joints.
 - Among them, **12 dogs also suffered from spondylosis** and symptoms of **cauda equina syndrome** (*31.6% of this subgroup*).
 - **26 dogs had OA of the elbows** and/or hips without diagnosed spinal issues (*68.4% of this subgroup*).
 - Body weight ranged from **10 to 45 kg**.
- **12 dogs with autoimmune joint inflammation** (*23.5% of dogs with feedback*):
 - In **8 cases** (66.7%), VETMIC® Dogs was administered without concurrent glucocorticoid therapy (GCS), and a marked improvement was observed.
 - In **4 dogs** (33.3%), GCS had to be introduced due to insufficient response to VETMIC® Dogs alone.

3. Study Results – Senior Dog Group (n = 38)

Dogs without spinal conditions (n = 26, 68.4%)

Average effectiveness score: ~8/10

Reported improvements:

- Significant pain reduction
- Improved joint mobility
- Increased physical activity
- Enhanced overall well-being (*owner-reported*)


Dogs with spinal conditions (n = 12, 31.6%)

Average effectiveness score: ~7/10

Reported outcomes:

- Noticeable improvement in quality of life
- Reduced pain symptoms
- Increased willingness to move

Note: Effectiveness was evaluated subjectively based on owner observation. Veterinary pain scales were not used. Parameters assessed included walk duration, willingness to play, and ease of standing and movement.



4. Results – Autoimmune Joint Inflammation Group (n = 12)

8 dogs (66.7%) responded positively to **VETMIC® Dogs** without requiring GCS:

- Inflammation symptoms either resolved or significantly diminished.

4 dogs (33.3%) required GCS to supplement therapy, suggesting variability in response depending on immune activity.

5. Conclusions and Recommendations

VETMIC® Dogs demonstrates notable effectiveness in improving comfort and mobility in dogs with advanced osteoarthritis, particularly when no neurological conditions are present.

In autoimmune joint inflammation, **VETMIC® Dogs** may serve a supportive or, in some cases, primary therapeutic role, especially for patients not requiring steroidal intervention.

Further research is advised to:

- Include objective pain and mobility scoring systems
- Be conducted on larger cohorts
- Evaluate long-term outcomes beyond the initial 4-week treatment window



Dr. Aneta Bocheńska DVM, PhD (Poland)